You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSertindole
Accession NumberDB06144
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionSertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. Like the other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market.
Structure
Thumb
Synonyms
1-[2-[4-[5-chloro-1-(4-Fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one
Serdolect
SerLect
Sertindol
Sertindole
Sertindolum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SerdolectNot Available
SerlectNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIGVV4Z879SP
CAS number106516-24-9
WeightAverage: 440.941
Monoisotopic: 440.177917386
Chemical FormulaC24H26ClFN4O
InChI KeyGZKLJWGUPQBVJQ-UHFFFAOYSA-N
InChI
InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)
IUPAC Name
1-(2-{4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]piperidin-1-yl}ethyl)imidazolidin-2-one
SMILES
FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
Pharmacology
IndicationUsed in the treatment of schizophrenia.
Structured Indications Not Available
PharmacodynamicsSertindole is an atypical antipsychotic at least as effective as haloperidol and risperidone in the treatment of neuroleptic-responsive schizophrenia. Sertindole improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. Sertindole is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS).
Mechanism of actionSertindole is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 2CProteinyes
antagonist
HumanP28335 details
5-hydroxytryptamine receptor 6Proteinyes
antagonist
HumanP50406 details
Potassium voltage-gated channel subfamily H member 2Proteinunknown
inhibitor
HumanQ12809 details
Alpha-1A adrenergic receptorProteinunknownNot AvailableHumanP35348 details
Alpha-1B adrenergic receptorProteinunknownNot AvailableHumanP35368 details
Alpha-1D adrenergic receptorProteinunknownNot AvailableHumanP25100 details
Related Articles
AbsorptionOrally available.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Sertindole is metabolized by cytochrome P450 isoenzymes CYP 2D6 and CYP 3A4.

Route of eliminationNot Available
Half life3 days
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Sertindole is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineSertindole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineSertindole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineSertindole may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineSertindole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Sertindole.Experimental
AbirateroneThe serum concentration of Sertindole can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Sertindole.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Sertindole.Approved
adipiplonThe risk or severity of adverse effects can be increased when Sertindole is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Sertindole is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Sertindole is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Sertindole.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Sertindole.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Sertindole.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sertindole.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Sertindole.Approved
AmiodaroneThe metabolism of Sertindole can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Sertindole is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Sertindole is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Sertindole.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Sertindole is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Sertindole is combined with Amperozide.Experimental
AmphetamineSertindole may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Sertindole.Approved, Investigational
AprepitantThe serum concentration of Sertindole can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sertindole.Approved, Investigational
ArtemetherThe metabolism of Sertindole can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Sertindole is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Sertindole is combined with Asenapine.Approved
AtazanavirThe metabolism of Sertindole can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Sertindole can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Sertindole is combined with Azaperone.Vet Approved
AzelastineSertindole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Sertindole is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Sertindole is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Sertindole.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Sertindole is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Sertindole.Approved
BenzphetamineSertindole may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Sertindole is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Sertindole can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Sertindole can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Sertindole can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Sertindole can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Sertindole can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Sertindole is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Sertindole.Approved, Illicit
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Sertindole.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Sertindole is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Sertindole is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sertindole.Approved, Investigational
BuprenorphineSertindole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Sertindole can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Sertindole.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sertindole.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Sertindole is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Sertindole is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Sertindole is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Sertindole.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sertindole.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sertindole.Approved
CarbamazepineThe metabolism of Sertindole can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Sertindole is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Sertindole.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Sertindole is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Sertindole can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Sertindole can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Sertindole is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Sertindole.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sertindole.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Sertindole.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sertindole.Approved
ChloroquineThe metabolism of Sertindole can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Sertindole is combined with Chlorphenamine.Approved
ChlorphentermineSertindole may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Sertindole can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sertindole.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Sertindole is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Sertindole can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Sertindole can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Sertindole can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sertindole.Approved, Vet Approved
CitalopramThe metabolism of Sertindole can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Sertindole can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Sertindole can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Sertindole is combined with Clidinium.Approved
ClobazamThe metabolism of Sertindole can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Sertindole is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Sertindole can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Sertindole is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Sertindole is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sertindole.Approved, Illicit
ClotrimazoleThe metabolism of Sertindole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Sertindole can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Sertindole can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Sertindole can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Sertindole.Approved, Illicit
ConivaptanThe serum concentration of Sertindole can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Sertindole can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Sertindole is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sertindole.Approved
CyclosporineThe metabolism of Sertindole can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Sertindole is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Sertindole can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Sertindole is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sertindole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Sertindole is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Sertindole can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Sertindole can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Sertindole can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Sertindole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Sertindole can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Sertindole is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Sertindole.Approved
DesipramineThe metabolism of Sertindole can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Sertindole is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Sertindole.Approved
DetomidineThe risk or severity of adverse effects can be increased when Sertindole is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Sertindole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Sertindole is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sertindole.Approved, Vet Approved
DextroamphetamineSertindole may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sertindole.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Sertindole.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sertindole.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Sertindole.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Sertindole.Approved, Illicit, Vet Approved
DiethylpropionSertindole may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Sertindole is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Sertindole.Approved, Illicit
DihydroergotamineThe metabolism of Sertindole can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Sertindole.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Sertindole.Experimental, Illicit
DiltiazemThe metabolism of Sertindole can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Sertindole is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Sertindole can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sertindole.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Sertindole is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Sertindole is combined with Doxepin.Approved
DoxycyclineThe metabolism of Sertindole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Sertindole is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Illicit
DronedaroneThe metabolism of Sertindole can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Sertindole.Experimental, Illicit
DuloxetineThe metabolism of Sertindole can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sertindole.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Sertindole.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Sertindole.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Sertindole is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Sertindole can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sertindole.Approved, Investigational
EliglustatThe metabolism of Sertindole can be decreased when combined with Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Sertindole.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Sertindole is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Sertindole can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertindole.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sertindole.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Sertindole.Approved
ErythromycinThe metabolism of Sertindole can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Sertindole.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Sertindole can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Sertindole.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sertindole.Approved
EthanolSertindole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertindole.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Sertindole is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Sertindole is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sertindole.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Sertindole.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Sertindole.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Sertindole is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Sertindole is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Sertindole is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sertindole.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Sertindole is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Sertindole.Illicit, Vet Approved
EtravirineThe serum concentration of Sertindole can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Sertindole is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Sertindole is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sertindole.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sertindole.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Sertindole is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Sertindole is combined with Flibanserin.Approved
FluconazoleThe metabolism of Sertindole can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Sertindole.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Sertindole is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Sertindole.Approved, Illicit
FluoxetineThe metabolism of Sertindole can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sertindole.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sertindole.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sertindole.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sertindole.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Sertindole is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Sertindole can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Sertindole can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sertindole can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Sertindole can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Sertindole is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Sertindole.Approved, Investigational
Fusidic AcidThe serum concentration of Sertindole can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sertindole.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Sertindole is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Sertindole.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Sertindole is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Sertindole.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Sertindole is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Sertindole.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Sertindole can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Sertindole.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Sertindole.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Sertindole.Approved
HydrocodoneSertindole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sertindole.Approved, Illicit
Hydroxyamphetamine hydrobromideSertindole may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved
IdelalisibThe serum concentration of Sertindole can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Sertindole is combined with Iloperidone.Approved
ImatinibThe metabolism of Sertindole can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Sertindole can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Sertindole is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Sertindole can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Sertindole can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sertindole.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Sertindole.Approved, Vet Approved
IsoniazidThe metabolism of Sertindole can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Sertindole can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Sertindole can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Sertindole can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Sertindole.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Sertindole.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Sertindole is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Sertindole can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Sertindole is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Sertindole is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Sertindole.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Sertindole is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Sertindole is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Sertindole.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Sertindole.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Sertindole.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sertindole.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sertindole.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Sertindole.Approved, Investigational
LisdexamfetamineSertindole may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Sertindole.Approved
LofentanilThe risk or severity of adverse effects can be increased when Sertindole is combined with Lofentanil.Illicit
LopinavirThe metabolism of Sertindole can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Sertindole is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sertindole.Approved
LorcaserinThe metabolism of Sertindole can be decreased when combined with Lorcaserin.Approved
LovastatinThe metabolism of Sertindole can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sertindole.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Sertindole.Investigational
LuliconazoleThe serum concentration of Sertindole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Sertindole can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Sertindole can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Sertindole is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Sertindole is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Sertindole is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Sertindole is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Sertindole.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Sertindole is combined with Melperone.Approved
MephedroneSertindole may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineSertindole may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sertindole.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sertindole.Approved, Illicit
MequitazineSertindole may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sertindole.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Sertindole is combined with Metaxalone.Approved
MethadoneThe metabolism of Sertindole can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Sertindole.Approved, Illicit
MethamphetamineSertindole may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Sertindole.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Sertindole.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Sertindole is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Sertindole.Approved
MethotrimeprazineSertindole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sertindole.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Sertindole is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Sertindole is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sertindole.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sertindole.Approved, Investigational
MetoprololThe metabolism of Sertindole can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineSertindole may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Sertindole.Approved, Illicit
MifepristoneThe serum concentration of Sertindole can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Sertindole.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Investigational
MirabegronThe metabolism of Sertindole can be decreased when combined with Mirabegron.Approved
MirtazapineSertindole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Sertindole can be decreased when it is combined with Mitotane.Approved
MMDASertindole may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Sertindole.Approved
ModafinilThe serum concentration of Sertindole can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Sertindole.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Sertindole.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Investigational
NafcillinThe serum concentration of Sertindole can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sertindole.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Sertindole.Approved, Investigational
NefazodoneThe metabolism of Sertindole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Sertindole can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Sertindole can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Sertindole can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Sertindole can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Sertindole can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Sertindole.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Sertindole is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Sertindole is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Sertindole is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sertindole.Approved, Investigational
OlaparibThe metabolism of Sertindole can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Sertindole is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sertindole.Approved
OpiumThe risk or severity of adverse effects can be increased when Sertindole is combined with Opium.Approved, Illicit
OrphenadrineSertindole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Sertindole.Investigational
OsimertinibThe serum concentration of Sertindole can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sertindole.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Sertindole is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Sertindole.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sertindole.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sertindole.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Sertindole.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Sertindole can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sertindole.Approved
PanobinostatThe serum concentration of Sertindole can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeSertindole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Sertindole can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Sertindole can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sertindole.Approved, Vet Approved
PentobarbitalThe metabolism of Sertindole can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved
PerazineThe risk or severity of adverse effects can be increased when Sertindole is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Sertindole is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sertindole.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sertindole.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sertindole.Approved
PhenobarbitalThe metabolism of Sertindole can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Sertindole is combined with Phenoxyethanol.Approved
PhentermineSertindole may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe metabolism of Sertindole can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Sertindole.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Sertindole is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Sertindole is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Sertindole.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Sertindole is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Sertindole is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Sertindole is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Sertindole can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleSertindole may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Sertindole is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Sertindole.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sertindole.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Sertindole is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Sertindole.Approved
PrimidoneThe metabolism of Sertindole can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Sertindole.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Sertindole.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sertindole.Approved, Vet Approved
PromazineThe metabolism of Sertindole can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Sertindole is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sertindole.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Sertindole.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Sertindole is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Sertindole is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Sertindole is combined with PSD502.Investigational
PseudoephedrineSertindole may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Sertindole.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sertindole.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Sertindole.Approved
QuinidineThe metabolism of Sertindole can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Sertindole can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Sertindole is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Sertindole is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Sertindole can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sertindole.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sertindole.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sertindole.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Sertindole.Approved
RifabutinThe metabolism of Sertindole can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Sertindole can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Sertindole can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Sertindole.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Sertindole is combined with Ritanserin.Investigational
RitobegronSertindole may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Sertindole can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Sertindole.Approved
RolapitantThe metabolism of Sertindole can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Sertindole is combined with Romifidine.Vet Approved
RopiniroleSertindole may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sertindole.Approved
RotigotineSertindole may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Sertindole.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Sertindole.Experimental
Sage 547The risk or severity of adverse effects can be increased when Sertindole is combined with Sage 547.Investigational
SaquinavirThe metabolism of Sertindole can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Sertindole is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sertindole.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Sertindole.Approved, Investigational, Vet Approved
SertralineThe metabolism of Sertindole can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sertindole.Approved, Vet Approved
SildenafilThe metabolism of Sertindole can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Sertindole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Sertindole can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved
St. John's WortThe serum concentration of Sertindole can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Sertindole can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sertindole.Approved, Investigational
SulfisoxazoleThe metabolism of Sertindole can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sertindole is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Sertindole.Approved, Investigational
SuvorexantSertindole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Sertindole is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Sertindole is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Sertindole.Approved
TelaprevirThe metabolism of Sertindole can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Sertindole can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Sertindole.Approved
TerbinafineThe metabolism of Sertindole can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sertindole.Approved
TetracaineThe risk or severity of adverse effects can be increased when Sertindole is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Sertindole.Investigational
ThalidomideSertindole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sertindole.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Sertindole.Approved, Vet Approved
ThioridazineThe metabolism of Sertindole can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sertindole.Approved
TiagabineThe risk or severity of adverse effects can be increased when Sertindole is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Sertindole is combined with Tiapride.Investigational
TiclopidineThe metabolism of Sertindole can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Sertindole is combined with Tiletamine.Vet Approved
TipranavirThe metabolism of Sertindole can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Sertindole is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Sertindole can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Sertindole is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Sertindole is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Sertindole.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Sertindole.Experimental
TranylcypromineThe metabolism of Sertindole can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Sertindole.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Sertindole.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sertindole.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sertindole.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Sertindole is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Sertindole is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Sertindole is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Sertindole.Approved, Investigational
VenlafaxineThe metabolism of Sertindole can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Sertindole can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Sertindole is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Sertindole.Approved
VoriconazoleThe metabolism of Sertindole can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Sertindole is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Sertindole is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sertindole.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Sertindole is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Sertindole is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Sertindole can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Sertindole is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sertindole.Approved, Investigational
ZolpidemSertindole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Sertindole is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Sertindole.Approved
ZotepineThe risk or severity of adverse effects can be increased when Sertindole is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sertindole.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Kane JM, Tamminga CA: Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin Investig Drugs. 1997 Nov;6(11):1729-41. [PubMed:15989577 ]
  2. Lewis R, Bagnall AM, Leitner M: Sertindole for schizophrenia. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001715. [PubMed:16034864 ]
  3. Perquin LN: Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol. 2005 Nov;20(6):335-8. [PubMed:16192844 ]
  4. Murdoch D, Keating GM: Sertindole : a review of its use in schizophrenia. CNS Drugs. 2006;20(3):233-55. [PubMed:16529528 ]
  5. Authors unspecified: Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation. Prescrire Int. 2007 Apr;16(88):59-62. [PubMed:17458045 ]
  6. Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. 2006 Sep;7(13):1825-34. [PubMed:16925508 ]
  7. Hertel P: Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse. 2006 Dec 1;60(7):543-52. [PubMed:16952163 ]
External Links
ATC CodesN05AE03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9781
Caco-2 permeable-0.7081
P-glycoprotein substrateSubstrate0.683
P-glycoprotein inhibitor IInhibitor0.903
P-glycoprotein inhibitor IIInhibitor0.7529
Renal organic cation transporterInhibitor0.6044
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6803
CYP450 1A2 substrateInhibitor0.7945
CYP450 2C9 inhibitorInhibitor0.5
CYP450 2D6 inhibitorNon-inhibitor0.6155
CYP450 2C19 inhibitorInhibitor0.624
CYP450 3A4 inhibitorInhibitor0.5802
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8995
Ames testNon AMES toxic0.6144
CarcinogenicityNon-carcinogens0.8988
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5452 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8038
hERG inhibition (predictor II)Inhibitor0.9186
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00963 mg/mLALOGPS
logP4.29ALOGPS
logP3.77ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)14.36ChemAxon
pKa (Strongest Basic)8.59ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.51 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity131.77 m3·mol-1ChemAxon
Polarizability47.17 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyrroles. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrole ring through a CC or CN bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyrroles
Sub ClassSubstituted pyrroles
Direct ParentPhenylpyrroles
Alternative Parents
Substituents
  • 1-phenylpyrrole
  • Indole or derivatives
  • Indole
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Chlorobenzene
  • Benzenoid
  • Piperidine
  • Imidazolidinone
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Heteroaromatic compound
  • Imidazolidine
  • Urea
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. 2006 Sep;7(13):1825-34. [PubMed:16925508 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Mork A, Witten LM, Arnt J: Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology (Berl). 2009 Sep;206(1):39-49. doi: 10.1007/s00213-009-1578-4. Epub 2009 Jun 9. [PubMed:19506838 ]
  4. Seeman P: Dopamine D2(High) receptors moderately elevated by sertindole. Synapse. 2008 May;62(5):389-93. doi: 10.1002/syn.20498. [PubMed:18293356 ]
  5. Cincotta SL, Rodefer JS: Emerging role of sertindole in the management of schizophrenia. Neuropsychiatr Dis Treat. 2010 Sep 7;6:429-41. [PubMed:20856607 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. 2006 Sep;7(13):1825-34. [PubMed:16925508 ]
  2. Schreiber R, Brocco M, Millan MJ: Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur J Pharmacol. 1994 Oct 13;264(1):99-102. [PubMed:7530204 ]
  3. Hietala J, Kuonnamaki M, Palvimaki EP, Laakso A, Majasuo H, Syvalahti E: Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment. Psychopharmacology (Berl). 2001 Sep;157(2):180-7. [PubMed:11594443 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. 2006 Sep;7(13):1825-34. [PubMed:16925508 ]
  2. Hietala J, Kuonnamaki M, Palvimaki EP, Laakso A, Majasuo H, Syvalahti E: Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment. Psychopharmacology (Berl). 2001 Sep;157(2):180-7. [PubMed:11594443 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Pouzet B, Didriksen M, Arnt J: Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol Biochem Behav. 2002 Apr;71(4):635-43. [PubMed:11888555 ]
  2. Mork A, Witten LM, Arnt J: Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology (Berl). 2009 Sep;206(1):39-49. doi: 10.1007/s00213-009-1578-4. Epub 2009 Jun 9. [PubMed:19506838 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Rampe D, Murawsky MK, Grau J, Lewis EW: The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther. 1998 Aug;286(2):788-93. [PubMed:9694935 ]
  2. Kang J, Chen XL, Rampe D: The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel. Biochem Biophys Res Commun. 2001 Aug 24;286(3):499-504. [PubMed:11511086 ]
  3. Tang W, Kang J, Wu X, Rampe D, Wang L, Shen H, Li Z, Dunnington D, Garyantes T: Development and evaluation of high throughput functional assay methods for HERG potassium channel. J Biomol Screen. 2001 Oct;6(5):325-31. [PubMed:11689132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. 2006 Sep;7(13):1825-34. [PubMed:16925508 ]
  2. Hietala J, Kuonnamaki M, Palvimaki EP, Laakso A, Majasuo H, Syvalahti E: Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment. Psychopharmacology (Berl). 2001 Sep;157(2):180-7. [PubMed:11594443 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. 2006 Sep;7(13):1825-34. [PubMed:16925508 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. 2006 Sep;7(13):1825-34. [PubMed:16925508 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on November 19, 2007 09:49 / Updated on August 17, 2016 12:24